|0.6333|| -0.0402 / -5.97%|
RXi Pharmaceuticals Corp. is a biotechnology company. It focuses on discovering, developing and commercializing innovative therapies based on its proprietary, new-generation RNA interference platform. RXi Pharmaceuticals proprietary therapeutic platform is comprised of novel RNAi compounds include rxRNAori and sd-rxRNA. Its clinical product candidate is RXI-109 a self-delivering RNAi compound developed for the reduction of dermal scarring in planned surgeries. RXI-109 is designed to reduce the expression of connective tissue growth factor a critical regulator of several biological pathways involved in scarring and fibrotic diseases. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
|Geert Cauwenbergh||President, CEO, CFO & Director|
|Karen Bulock||Vice President-Research|
|Lyn Libertine||Vice President-Medical Affairs & Safety Assessment|
|Pamela A. Pavco||Chief Development Officer|
|Alexey V. Eliseev||Chief Business Officer|